Profit

NSE Symbol: | BSE Code: | ISIN: | Sector:

  • Add to Portfolio
  • Add to Watchlist
  • Add to Alert
  • Add to Message
Add to Portfolio
NSE
598.25
Change Change %
7.45 1.26%

Updated:23 Aug, 2019, 15:58 PM IST

BSE
600.25
Change Change %
9.40 1.59%

Updated:23 Aug, 2019, 16:01 PM IST

Aurobindo Pharma was founded in 1986 by Mr. P. V. Ramaprasad Reddy and Mr. K. Nityananda Reddy. It started its operation with a single unit manufacturing semi synthetic penicillin (SSPs) at Pondicherry.

It has a product presence in key therapeutic segments like SSPs, cephalosporins, antivirals, CNS, cardio–vascular, gastroenterology, etc. The company is the market leader in semi–synthetic penicillin drugs.

It has set up overseas branches/ representative offices located in Ethiopia, Tanzania, Kenya, Uganda, Italy, Ghana, Vietnam, and United Kingdom.

Aurobindo Pharma has identified international operations, catering to over 100 countries, as a major engine of growth and expanding global network of marketing and manufacturing operations across countries like China, Brazil, Japan, Netherlands, South Africa, Thailand, UK, USA, Russia, Netherlands and many more which will further expand its international reach. Subsidiaries in strategic pharmaceutical markets have positioned it to ride the challenges, powered by the strengths, the brilliance and hard work of its global workforce, stellar track record, ever–growing infrastructure and cost–competitiveness.

Aurobindo has invested significant resources in building a mega infrastructure for APIs and formulations to emerge as a vertically integrated pharmaceutical company. Aurobindo’s five units for APIs and four units for formulations are designed for the regulated markets.

Its manufacturing units is approved by USFDA, UKMHRA, WHO, MCC–SA and ANVISA–Brazil

In 2012 Aurobindo Pharma commenced business journey into peptides segment. Aurobindo Pharma Ltd. launched its operations in the Kingdom of Bahrain through a grand event held at Hotel Radisson Blu on Monday, 17th Sep’2012.

In April 2014 Aurobindo Pharma Limited announced the completion of the previously announced acquisition of certain commercial operations in Western Europe from Actavis plc (NYSE: ACT). The agreement to acquire the Actavis operations was announced in January 2014.

Products

Formulation– In this segment it manufactures formulation for cardio vascular, central nervous system, gastroenterologicals, anti–retrovirals and anti–infectives. It has developed formulations namely Trandolapril, Captopril, Benazepril Hydrochloride, etc.

Active Pharmaceutical Ingredients (API) – Aurobindo’s five units for APIs and four units for formulations are designed for the regulated markets.

Organic Intermediates– It manufactures wide range of organic intermediates namely Desmethyl Azithromycin, Methanamine, Benzimidazole, ECPPA and many more.

Awards

In 2011 Aurobindo Pharma received Platinum Certificate of Outstanding Exports Award from Pharmexcil.





Top